Alcázar-Navarrete, B., Figueira-Gonçalves, J. M., Blanco Cid, N., Bruguera Avila, N., Bernabeu Mora, R., Fuster Gomila, A., . . . Sánchez-Covisa, J. (2026). Real-World Outcomes across Baseline Risk Profiles in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate in Spain: Insights from the ORESTES Study. Pulmonary Therapy, 12(2), 667. https://doi.org/10.1007/s41030-026-00366-x
Παραπομπή σε μορφή Chicago (17η εκδ.)Alcázar-Navarrete, Bernardino, et al. "Real-World Outcomes Across Baseline Risk Profiles in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate in Spain: Insights from the ORESTES Study." Pulmonary Therapy 12, no. 2 (2026): 667. https://doi.org/10.1007/s41030-026-00366-x.
Παραπομπή σε μορφή MLA (9th εκδ.)Alcázar-Navarrete, Bernardino, et al. "Real-World Outcomes Across Baseline Risk Profiles in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate in Spain: Insights from the ORESTES Study." Pulmonary Therapy, vol. 12, no. 2, 2026, p. 667, https://doi.org/10.1007/s41030-026-00366-x.